local_hospital

Dr Sekowska Leczenie Bolu

Address
ul. Wolnosc 2, lok. 5U-80, 01-018 Warsaw, Poland

Immune System Diseases at Dr Sekowska Leczenie Bolu

The site is conducting clinical research in immune system diseases, focusing on conditions such as moderate to severe atopic dermatitis, moderate to severe chronic spontaneous urticaria, and alopecia areata. These studies are designed to assess new treatment options and compare them with placebo to better understand symptom control and disease improvement.

  • Atopic dermatitis treatment effectiveness
  • Chronic spontaneous urticaria symptom control
  • Alopecia areata hair regrowth research

This research aims to improve care for patients with inflammatory and immune-related skin conditions by evaluating whether new therapies can offer better relief and visible clinical benefit.

Nervous System Diseases

Clinical trials at this Warsaw site also address nervous system diseases, with a strong emphasis on migraine and related headache disorders, including migraine attacks with or without aura and menstrual migraine. The research is centered on finding better ways to prevent attacks and improve short-term relief for people living with frequent migraines.

  • Migraine prevention strategies
  • Acute migraine treatment
  • Menstrual migraine prevention

These studies are evaluating whether newer therapies can reduce migraine burden, improve pain relief, and support patients who have not responded well to standard preventive medicines.

Skin and Connective Tissue Diseases

The research portfolio at Dr Sekowska Leczenie Bolu includes trials in skin and connective tissue diseases, especially conditions that affect daily comfort, appearance, and quality of life. The main focus is on testing therapies that may ease inflammation, reduce symptoms, and improve visible skin outcomes.

  • Atopic dermatitis inflammation relief
  • Urticaria management
  • Skin disease treatment evaluation

Overall, the site contributes to clinical studies that aim to refine treatment choices for chronic dermatologic conditions and support better long-term disease control.

Site Overview

assignment
2
connected trials
corporate_fare
1
sponsor
science
1
IMP

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
1
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
2
Outperforms 43% of sites
public
Therapeutic diversity
2areas
Outperforms 53% of sites
groups
Sponsor diversity
1sponsors
Outperforms 1% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Dr Sekowska Leczenie Bolu

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Phase 3 Double-Blind Study on Rimegepant for Intermittent Prevention of Menstrual Migraine in Women Aged 18-45Pfizer Inc.Phase IIINot RecruitingOct 2025

IMP list

IMP Trials Status First start Last start
Rimegepant1Unknown2025-10-172025-10-17

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.